Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 22;44(8):3267-3282.
doi: 10.3390/cimb44080225.

Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review

Giulia Poletto  1 , Diego Cecchin  1 , Paola Bartoletti  1 , Francesca Venturini  2 , Nicola Realdon  3 , Laura Evangelista  1
Affiliations
Review

Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review

Giulia Poletto et al. Curr Issues Mol Biol. .

Abstract

The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms "radionuclides", "liposomes", "avidin-biotin interaction", "theranostic", and "molecular docking". The 10 year filter was applied, except for the avidin-biotin interaction. Data were retrieved from both preclinical and clinical settings. Three targeting strategies were considered: pretargeting, liposomes, and ligands. Pretargeting can be achieved by exploiting the avidin-biotin interaction. This strategy seems very promising, although it has been investigated mainly in resectable tumors. Radiolabeled liposomes have attracted new interest as probes to identify the most suitable patients for treatment with liposomal formulations of common chemotherapeutics. The use of ligands for the delivery of radiotherapeutics to a specific target is still the most appealing strategy for treating tumors. The most appropriate ligand can be identified by virtually simulating its interaction with the receptor. All strategies showed great potential for use in targeted radionuclide therapy, but they also have numerous drawbacks. The most promising option is probably the one based on the use of new ligands.

Keywords: avidin–biotin; docking; liposomes; targeted radionuclide therapy.

PubMed Disclaimer

Conflict of interest statement

D.C. received research and travel grants from Life Molecular Imaging and General Electric, as well as travel grants from Curium, but they were unrelated to the content of the present review. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram. Description of the search strategy and exclusion/inclusion criteria.
Figure 2
Figure 2
Scheme of the two-step (A) and three-step (B) protocols.
Figure 3
Figure 3
Schematic application of liposomes (a) and the avidin–biotin interaction (b) in clinical trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gill M.R., Falzone N., Du Y., Vallis K.A. Review targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18:e414–e423. doi: 10.1016/S1470-2045(17)30379-0. - DOI - PubMed
    1. Gudkov S.V., Shilyagina N.Y., Vodeneev V.A., Zvyagin A.V. Targeted radionuclide therapy of human tumors. Int. J. Mol. Sci. 2015;17:33. doi: 10.3390/ijms17010033. - DOI - PMC - PubMed
    1. Artigas C., Mileva M., Flamen P., Karfis I. Targeted radionuclide therapy: An emerging field in solid tumours. Curr. Opin. 2021;33:493–499. doi: 10.1097/CCO.0000000000000762. - DOI - PubMed
    1. Peltek O.O., Muslimov A.R., Zyuzin M.V., Timin A.S. Current outlook on radionuclide delivery systems: From design consideration to translation into clinics. J. Nanobiotechnol. 2019;17:90. doi: 10.1186/s12951-019-0524-9. - DOI - PMC - PubMed
    1. Malcolm J., Falzone N., Lee B.Q., Vallis K.A. Targeted radionuclide therapy: New advances for improvement of patient management and response. Cancers. 2019;11:268. doi: 10.3390/cancers11020268. - DOI - PMC - PubMed

LinkOut - more resources